Thu, Jul. 21, 4:18 AM
- Helped by cost-control measures, Unilever (NYSE:UL) posted a profit rise and said it's ready for challenges ahead.
- Swatch (OTCPK:SWGAY) expects a recovery in the second half after net profit plunged 52% in H1.
- Roche (OTCQX:RHHBY) confirmed its outlook for 2016 and reported results that exceeded expectations.
- Driven by price and mix realization, SABMiller's (OTCPK:SBMRY) group net producer revenue grew 2% in Q1.
- Lufthansa (OTCQX:DLAKY) cut its full-year profit target, saying "terrorist attacks in Europe" weighed on its bookings.
- The fears also hit Easyjet (OTCQX:ESYJY), with shares under pressure after weak Q3 revenues.
Thu, Jan. 28, 4:15 AM
- Deutsche Bank (NYSE:DB) -1% premarket after posting a full-year loss of €6.8B, as writedowns, litigation charges and restructuring costs took their toll.
- Electrolux (OTCPK:ELUXY) slumped to a Q4 loss after costs from its failed GE deal weighed on results.
- A strong dollar hit purchasing costs at H&M (OTCPK:HNNMY), resulting in a set of relatively lackluster earnings.
- Roche (OTCQX:RHHBY) reported 5% fall in full-year net income as the strong Swiss franc countered gains from the company’s diagnostics and cancer treatment units.
Aug. 24, 2015, 1:33 PM
- Roche (OTCQX:RHHBY) has struck a deal with U.K. molecular diagnostics firm Lumora to buy "products associated with [Lumora's] unique, patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded (FFPE) tumor samples." Terms are undisclosed.
- Roche: "Today, nucleic acid purification technology from specimens including formalin-fixed tissues can be cumbersome and inefficient. Lumora's highly differentiated proprietary methodology will enable simple and automated nucleic acid isolation in minutes instead of hours. In addition, the technology is environmentally friendly and can be applied to process a wide variety of sample types including whole blood, fecal matter, sputum, FFPE tissue and buccal swabs."
- The drug giant adds it plans to explore integrating Lumora's technology into its sequencing workflow solution.
Jan. 28, 2015, 3:23 AM
- Missing analysts’ forecasts, Roche (OTCQX:RHHBY) said net income attributable to shareholders fell to 9.33B francs ($10.34B) from 11.16B francs a year earlier, despite rising sales of its cancer treatments.
- The company said it was hit by impairments, restructuring costs and debt restructuring.
- Roche expects sales this year to grow in low-to-mid single digits range, while core earnings per share should grow more than sales.
- Roche shares are down 1.3% in Switzerland.
Jan. 12, 2015, 2:14 AM
- Roche (OTCQX:RHHBY) is acquiring a majority of Foundation Medicine (NASDAQ:FMI) for more than $1B, by buying a combination of outstanding and newly issued shares for a 52.4%-56.3% stake on a fully diluted basis.
- Foundation is the leader in the growing area of sequencing the genes of tumor samples, looking for mutations that can help predict which drug will be most effective for a particular patient.
Dec. 29, 2014, 5:47 AM
- The FDA has given emergency approval for Roche's (OTCQX:RHHBY) LightMix Ebola Zaire rRT-PCR Test, helping health care authorities fight the current outbreak of the deadly disease.
- The test can generate results in about three hours and would allow "health-care professionals to quickly detect the virus and start patient treatment as early as possible," said Roland Diggelman, chief operating officer at Roche’s diagnostics division.
Nov. 23, 2014, 3:21 PM
- Group says Genentech's (OTCQX:RHHBY) change to distribution of oncology drugs will negatively impact U.S. hospitals, clinics, and their patients.
- Says that while the distribution shift may improve Genentech's model, "it does so at the expend of the efficiencies, quality and safety within U.S. hospitals and clinics."
- Asks that Genentech "reverse this ill-advised decision."
- Source: Gautam Kollu
Aug. 24, 2014, 5:31 PM
- Roche (OTCQX:RHHBY, OTCPK:RHHBF) will pay $74/share for InterMune (NASDAQ:ITMN), a 38% premium to its Friday close and 63% higher than Aug. 12 when news of a potential sale emerged.
- The deal gives Roche access to pirfenidone, which targets idiopathic pulmonary fibrosis, a disease that causes tissue deep in the lungs to become thick and scarred over time. Analysts predict pirfenidone will generate $1B in global sales by 2019.
- Pirfenidone joins Roche’s stable of pulmonary treatments, including Pulmozyme for cystic fibrosis, Xolair for asthma, and in-development asthma drug lebrikizumab. Roche plans to speed pirfenidone’s U.S. start-up and help get insurance coverage for the medicine.
Aug. 17, 2014, 8:12 AM
- Chugai Pharmaceutical (OTCPK:CHGCY) denies a rumor that surfaced Friday, which stated that Roche (OTCQX:RHHBY) was in talks to buy the 40% stake of Chugai that it does not already own for $10B.
- The media report "is not based on any announcement made by Chugai or Roche," says the Japanese company in a news release.
- Previously: Roche may gobble up the rest of Chugai
Jul. 20, 2014, 10:42 AM
- Roche (OTCQX:RHHBY) plans to continue its strategy of focusing on smaller acquisitions and partnerships rather than the big M&A deals that have been spreading across the healthcare industry.
- "We're sticking to our previous strategy. This includes targeted, small acquisitions and partnerships like the ones we have carried out in recent months," says CEO Severin Schwan. "We have to weigh up internal and external opportunities. It can't be that we have to put important internal opportunities on ice because of too-expensive acquisitions."
- The company has acquired a few small diagnostic companies this year including the recent purchase of Seragon Pharmaceuticals and Genia Technologies.
Jul. 2, 2014, 2:36 AM
- Roche (RHHBY) has announced it will buy Seragon, a breast cancer research company, for $725M. The company may pay up to another $1B based on future performance. Seragon was spun out from Aragon Pharmaceuticals last year, when the latter was purchased for $650M by Johnson & Johnson.
- Seragon is the second major acquisition for Roche in the last two months. The company bought Genia Technologies for up to $350M in in June.
Apr. 7, 2014, 7:08 AM
- Roche (RHHBF) has acquired privately held IQuum for up to $450M in a deal that will boost the Swiss company's molecular diagnostics business.
- Roche will pay $275M up front and $175M in product-related milestones.
- IQuum says its "lab-in-a-tube technology" enables "non-specialized personnel to perform more sophisticated biological sample testing in any setting." (PR)
Mar. 27, 2014, 4:26 AM
- Novartis' (NVS) Ceritinib (LDK378) reduced the size of tumors in 58% of patients in a Phase I study of those suffering from a form of lung cancer that strikes 10,000 people a year in the U.S.
- Ceritinib is the leader of a class of drugs that targets a gene known as ALK and is 20 times as effective as a drug from Pfizer (PFE) called Xalkori.
- However, patients developed resistance to Ceritinib and the median time for progression-free survival was seven months.
- The study involved 114 subjects, and while it was only Phase I, Novartis is using the results to file for FDA approval based on the drug's "breakthrough therapy designation."
- Other companies developing ALK inhibitors include Ariad Pharmaceuticals (ARIA), and Roche (RHHBF) and Japan's Chugai (CHGCY) together, while Pfizer is working on a follow-on to Xalkori. (PR)
Mar. 13, 2014, 7:25 AM
- An FDA federal advisory committee has unanimously recommended the approval of a DNA test developed by Roche (RHHBF) as the primary screening tool for cervical cancer in women.
- The product would be used alone on women aged 25 and older, and could eventually supersede the PAP test, which has been around for 60 years.
- The market for Roche's test and those of other companies is worth over $200M.
Mar. 12, 2014, 7:51 AM
- France's competition authority is investigating Novartis (NVS) and Roche over whether they conspired to prevent the use of Roche's (RHHBY) Avastin to treat vision problems in favor of the more expensive drug Lucentis, which the companies co-promote.
- The news comes after Italy last week fined the firms a combined €182.5M over similar accusations.
Mar. 10, 2014, 10:00 AM
- The WSJ profiles "pharmaceutical scouts," who, like talent-spotters in baseball "trying to pick tomorrow's big-leaguers from farm teams," search outside their companies to find drug candidates that have the potential to become blockbusters.
- In 2011, for instance, Johnson & Johnson's (JNJ) Peter Lebowitz helped his company beat competitors such as Novartis (NVS) to buy the rights to a blood-cancer drug from Pharmacyclics (PCYC) called Imbruvica.
- The treatment was eventually approved in November for a rare lymphoma and for chronic lymphocytic leukemia in February. J.P. Morgan forecasts Imbruvica will generate $1.3B in revenue for J&J in 2017.
- Half of J&J's drug pipeline is from outside the company, up from 20% in 2002.
- Other related tickers: MRK, RHHBY, BMY, SNY, CELG, GSK
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and... More
Industry: Drug Related Products
Other News & PR